Immunomedics Announces Abstract on Sacituzumab Govitecan (IMMU-132) in …

Immunomedics Announces Abstract on Sacituzumab Govitecan (IMMU-132) in …

IMMU-132 has received Breakthrough Therapy Designation from FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to …

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Write a comment

*